

Our Ref: 439/2023
September 2023

Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information query regarding the use of Biologic medicines in Dermatology. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira - 1
- Adalimumab Biosimilar - 27
- Apremilast - 44
- Bimekizumab - 0
- Brodalumab - 7
- Certolizumab - 2
- Deucravacitinib - 0
- Dimethyl fumarate - 1
- Etanercept – Enbrel - 1
- Etanercept Biosimilar - 0
- Guselkumab - 39
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 0
- Ixekizumab - 8
- Risankizumab - 0
- Secukinumab - 0
- Tildrakizumab - 1
- Ustekinumab - 13

Q2. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:

- Ciclosporin
- Methotrexate - any form and strength
- Methotrexate injections 15mg and above

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.